Document is current
Any future updates will be listed below
-
Authors
Langlois, Julie
Lange, Simona
Ebeling, Martin
Macnair, Will
Schmucki, Roland
Li, Cenxiao
DeGeer, Jonathan
Sudharshan, Tania J. J.
Yong, V. Wee
Shen, Yun-An
Harp, Christopher
Collin, Ludovic
Keaney, James
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd
MS Canada, the Canadian Institutes of Health Research
USA Department of Defense Multiple Sclerosis Research Program
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 18 October 2024
First Online: 27 October 2024
Declarations
:
: All iPSC lines used in this study were obtained and used with informed consent. The use of autopsied human brain tissues for immunofluorescence analyses in this study has been approved by the Conjoint Health Research Ethics Board at the University of Calgary (Ethics ID REB15-0444).
: Not applicable.
: JL, SL, ME, WM, RS, JD, TS, LC and JK were employees and shareholders of F. Hoffmann-La Roche Ltd during the time that this work was completed. YS and CH were employees of Genentech, Inc., and shareholders of F. Hoffmann-La Roche Ltd during the time this work was completed. VWY has research contracts with Genentech, Inc. and Novartis. He has received speaker honoraria from Biogen Idec, EMD Serono (Merck), Novartis, F. Hoffmann-La Roche Ltd, Sanofi Genzyme and Teva Canada. He is the recipient of unrestricted educational grants from Biogen Idec, EMD Serono (Merck), Novartis, F. Hoffmann-La Roche Ltd, Sanofi Genzyme and Teva Canada to support educational activities of the Alberta MS Network and Americas School of Neuroimmunology of the International Society of Neuroimmunology, which he directs.
